Navigation Links
Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
Date:10/11/2007

AURORA, ON, Oct. 11 /PRNewswire-FirstCall/ - Helix BioPharma Corp. (TSX: HBP / Frankfurt: WKN 918864) announced today the addition of Kenneth D. Hatch, M.D., as a new medical advisor to the Company. Dr. Hatch will provide guidance to Helix on its clinical-stage compound, Topical Interferon Alpha-2b, for the treatment of conditions caused by HPV. Dr. Hatch is a professor of obstetrics and gynecology at the University of Arizona.

"Dr. Hatch complements our medical advisory team and brings additional strength to Helix' expertise in the field of gynecology and pre-invasive diseases of the cervix", said John Docherty, vice president, corporate development at Helix. "We are very pleased to establish this relationship with Dr. Hatch, and expect that he will be an invaluable asset to the Company as we continue to move forward with the preparations for our planned IND/CTA filings for Topical Interferon Alpha-2b".

Previously, Dr. Hatch was president of the American Society of Colposcopy and Cervical Pathology. Dr. Hatch has also presided as secretary-treasurer of the International Federation of Colposcopy and Cervical Pathology, and as president of the Society of Gynecologic Oncologists.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b, for the treatment of conditions caused by HPV, and its novel L-DOS47 new drug product candidate for the treatment of lung adenocarcinoma. Helix is listed on the Toronto Stock Exchange under the ticker symbol "HBP".

This News Release contains certain forward-looking statements and information regarding Helix's product development initiatives, Topical Interferon Alpha-2b and L-DOS47. Forward-looking statements and inform
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...hursday, November 5, 2009 at 4:30 p.m. Eastern Tim...ire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (...ay reported unaudited financial results for the th...09 and reviewed the Company,s highlights for the t...ated results reflect the operations of OncoGenex T...
(Date:11/5/2009)...ber 5, 2009 Senomyx, Inc...prietary taste receptor-based technologies to disc...ge, and ingredient supply industries, today provid...ts for the third quarter ended September 30, 2009.... of 2009, compared to $4.0 million for the third q...
(Date:11/5/2009)...LASIK Surgery and vision correction experts listed...vely involved at the recently concluded American A...in San Francisco, California. Dr. Stephen Brint, M...idorf, MD, Dr. Peter Rapoza, MD, Dr. Michael Raizm...n, MD, Dr. Edward Manche, MD, and Dr. Parag Majmud...
(Date:11/4/2009).... 4 Star Scientific, I...mpany plans to introduce the CigRx(TM) nutraceutic... Pharmaceuticals, for worldwide marketing and sale...asdaq: VTIV). inVentiv Health offers a complete r...e of the product lifecycle, in a range of healthca...
Breaking Biology Technology:OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 2Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 3Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 5Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 6Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 7Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 8Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 9Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health 2Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health 3Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health 4
...ype 2 Diabetic Volunteers, JERUSALEM, September 9...http://www.oramed.com ), a developer,of oral deliv...eement with,ETI Karle Clinical Pvt. Ltd. ( http://...ation (CRO) located in India, to conduct Phase 2B ...e study is intended to evaluate the safety, tolera...
...DeVasto, CPA, President and,Chief Executive Office...tants and Business Consultants, is pleased to anno... WolfPAC(sm) risk assessment module., WolfPAC(sm)... an easy,to use, Internet-based system to evaluate...tigate the risk. The scalable, multi-module soluti...
...ntments Strengthen Executive Team, FREMONT, Calif...pharmaceutical company developing a novel transder... Schulze has joined the,company as chair and CEO. ...ents to the Zosano leadership team, including Don ... M. Vuko, executive vice president and,chief finan...
Other Biology Technology:Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801 2Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801 3WolfPAC(sm) Integrated Risk Management Announces 100th Sale 2Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 2Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 3Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 4
(Date:11/3/2009)...he UCLA Henry Samueli School of Engineering and Ap... reconstituted in the laboratory the enzyme respon...wering drug lovastatin. , The research, publi...tially lead to the development of other compounds ...statin-synthesizing enzyme is one of the most inte...
(Date:11/3/2009)... Nov. 3 EmSense Corporation, the c...al and brainwave measurement technology, today ann...nd of funding, led by an investment from Technolog...p also participating. ,, This funding will allo...ort of its many market research partners. The fun...
(Date:11/2/2009)...BER 27, 2009 Agriculture is going through a prof...revolution of the 19th century and the green revol...a new book, Organic Farming: The Ecological Syste...th the best that science has to offer. The book,s ...organic systems can be designed to meet human need...
Breaking Biology News(10 mins):UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatin 2EmSense Raises $9 Million Series C Round of Financing 2Ecology in organic ag: Combining farming, science 2US Farms Inc Aloe Vera Products Now Available on eBay 59223 1US Farms Inc Aloe Vera Products Now Available on eBay 59223 2US Farms Inc Aloe Vera Products Now Available on eBay 59223 3Saks Key to the Cure Shopping Weekend to Benefit Henry Ford Health System 59218 1BioMarins Chief Executive Jean Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times 14411 1BioMarins Chief Executive Jean Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times 14411 2BioMarins Chief Executive Jean Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times 14411 3BioMarins Chief Executive Jean Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times 14411 4
...covery that sheds new light upon the growth and de...rful but somewhat mysterious components of the bod...se against cancer and infectious diseases. , Scien...are generated in bone marrow, but Michael Caligiur... and the senior author of the study, says research...
...ntific world has accepted for more than 100 years,...eir grandparents, bypassing genetic abnormalities ...nts apparently have hidden templates containing ge...at can be transferred to their offspring, even tho...rding to Purdue University researchers. This disco...
... severe malaria before they reach hospital, has th... this week,s BMJ. , Every year over a million chi...talities occur outside hospital, especially in rur...lf of deaths occur within 24 hours of admission. ,...t possible to administer outside hospital, so buyi...
Other Biology News:Scientists identify new model Of NK cell development 2Scientists identify new model Of NK cell development 3Plants defy Mendel's inheritance laws, may prompt textbook changes 2Plants defy Mendel's inheritance laws, may prompt textbook changes 3
Human TIMP-1 ELISpot Kit from R&D Systems
...potent vasoconstrictor peptide. Displays selectivi...ascular tonus. ET-1, ET-2, and ET-3 are the produc...-3 are similar to ET-1, but differ in two and six ...roduce strong in vitro vasoconstrictor and in vivo...
Mouse Anti-HNF-1 Monoclonal Antibody, Unconjugated, Clone 2 from BD Biosciences Pharmingen
Baculovirus system service from Abgent
Biology Products: